Market research
FBRX Forte Biosciences Inc
PINK USD Healthcare
Latest close
As of 27 Aug 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 73
- Dividend yield
- Not available
- Beta
- 2.65
Profile
Instrument facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 73
- Dividend yield
- Not available
- Beta
- 2.65
About
About Forte Biosciences Inc
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary of argenx SE.
Research context
Forte Biosciences Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the FBRX discussion.
5 years, 6 months ago
Forte Biosciences, Inc is currently in a long term downtrend where the price is trading 9.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Forte Biosciences, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 56.8% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 65.9% to $-4M since the same quarter in the previous year.
Based on the above factors, Forte Biosciences, Inc gets an overall score of 3/5.